Section of Pulmonary and Critical Care Medicine, The University of Chicago, Chicago, IL 60637, USA.
Respir Res. 2011 Apr 10;12(1):44. doi: 10.1186/1465-9921-12-44.
While lung transplantation is an increasingly utilized therapy for advanced lung diseases, chronic rejection in the form of bronchiolitis obliterans syndrome (BOS) continues to result in significant allograft dysfunction and patient mortality. Despite correlation of clinical events with eventual development of BOS, the causative pathophysiology remains unknown. Airway epithelial cells within the region of inflammation and fibrosis associated with BOS may have a participatory role.
Transplant derived airway epithelial cells differentiated in air liquid interface culture were treated with IL-1β and/or cyclosporine, after which secretion of cytokines and growth factor and gene expression for markers of epithelial to mesenchymal transition were analyzed.
Secretion of IL-6, IL-8, and TNF-α, but not TGF-β1, was increased by IL-1β stimulation. In contrast to previous studies using epithelial cells grown in submersion culture, treatment of differentiated cells in ALI culture with cyclosporine did not elicit cytokine or growth factor secretion, and did not alter IL-6, IL-8, or TNF-α production in response to IL-1β treatment. Neither IL-1β nor cyclosporine elicited expression of markers of the epithelial to mesenchymal transition E-cadherin, EDN-fibronectin, and α-smooth muscle actin.
Transplant derived differentiated airway epithelial cell IL-6, IL-8, and TNF-α secretion is not regulated by cyclosporine in vitro; these cells thus may participate in local inflammatory responses in the setting of immunosuppression. Further, treatment with IL-1β did not elicit gene expression of markers of epithelial to mesenchymal transition. These data present a model of differentiated airway epithelial cells that may be useful in understanding epithelial participation in airway inflammation and allograft rejection in lung transplantation.
虽然肺移植是治疗晚期肺部疾病的一种越来越常用的疗法,但以闭塞性细支气管炎综合征(BOS)形式出现的慢性排斥反应仍然导致移植物功能显著受损和患者死亡。尽管临床事件与最终发生 BOS 相关,但致病的病理生理学仍然未知。与 BOS 相关的炎症和纤维化区域内的气道上皮细胞可能具有参与作用。
在气液界面培养中分化的移植源性气道上皮细胞用白细胞介素 1β(IL-1β)和/或环孢素处理,然后分析细胞因子和生长因子的分泌以及上皮间质转化标志物的基因表达。
IL-1β刺激可增加白细胞介素 6(IL-6)、白细胞介素 8(IL-8)和肿瘤坏死因子-α(TNF-α)的分泌,但不增加转化生长因子-β1(TGF-β1)的分泌。与先前使用浸没培养生长的上皮细胞进行的研究相反,在 ALI 培养中用环孢素处理分化细胞不会引起细胞因子或生长因子的分泌,也不会改变 IL-1β 处理时对 IL-6、IL-8 或 TNF-α的产生。IL-1β 和环孢素均未引起上皮间质转化标志物 E-钙黏蛋白、EDN-纤维连接蛋白和α-平滑肌肌动蛋白的表达。
体外移植源性分化气道上皮细胞的 IL-6、IL-8 和 TNF-α 分泌不受环孢素调节;因此,这些细胞可能参与免疫抑制状态下的局部炎症反应。此外,用 IL-1β 处理不会引起上皮间质转化标志物的基因表达。这些数据提供了一个分化气道上皮细胞的模型,可用于理解上皮细胞在肺移植中的气道炎症和移植物排斥反应中的作用。